ClinicalTrials.gg
CompletedNCT04795752Updated Nov 24, 2025Results posted

Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

An interventional study of TearCare System and Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion in Dry Eye and Meibomian Gland Dysfunction, sponsored by Sight Sciences, Inc.. Completed at 14 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Sight Sciences, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
55th of 473
345 · median 60
Started
2021
with 38 others
No phase
136 of 544
10 open now
Registered
365th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 55th largest by enrollment of the 473 interventional ones that give a count, is one of 39 that started in 2021, is one of 136 with no phase, and was the 365th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.

Read the detailed description

In this prospective, multicenter, randomized, active-controlled trial, TearCare is compared to cyclosporine 0.05% ophthalmic emulsion (Restasis) in eyes with dry eye disease (DED). Subjects randomized to TearCare receive TearCare treatment at baseline and Month 5, while subjects randomized to Restasis dose twice-daily with Restasis from baseline through Month 6. Primary inference is based on outcomes at the Month 6 visit including the co-primary endpoints tear break-up time (TBUT) and Ocular Surface Disease Index (OSDI).

03

Conditions studied

  • Dry Eye
  • Meibomian Gland Dysfunction
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 22 years of age
  • Reports dry eye symptoms within the past 3 to 6 months
  • Reports having to use artificial tears or lubricants regularly over the past month to relieve dry eye symptoms.
  • Schirmer tear test (with anesthesia) ≥1 to ≤10 mm in 5 minutes
  • OSDI Score of 23-79
  • TBUT of ≥1 to ≤7 seconds in both eyes
  • Meibomian gland obstruction in both eyes based on a total Meibomian Gland Secretion Score ≤12 in each eye.
  • At least 15 glands in each lower eyelid should be expressible, with a sterile cotton swab, at the slit lamp.
  • Best corrected visual acuity of 20/100 or better in both eyes.
  • Willing and able to comply with the study procedures and follow-up
  • Willing and able to provide
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • Use of any of the following medications:

    1. Cyclosporine (Restasis, Cequa etc.) or Xiidra within 60 days prior to enrollment;
    2. Antihistamines (oral or topical) within 10 days prior to enrollment;
    3. Systemic medication(s) (other than antihistamines) that is known to cause ocular dryness (e.g. diuretics, anti-hypertensives, anti-depressants, hormone therapy) and whose dose of this medication(s) has not been stable within 30 days prior to enrollment. There must be no anticipated adjustments to the dose of these medications for the duration of the trial;
    4. Accutane (at any time);
    5. Oral tetracyclines or azithromycin within 30 days prior to enrollment; or
    6. Topical ophthalmic antibiotics, anti-glaucoma medications, , non-steroidal anti- inflammatory medications within 30 days prior to enrollment.
  • Any of the following dry eye treatments:

    1. Office-based dry eye treatment (e.g. IPL, TearCare, thermal pulsation [Lipiflow], iLux etc.) within 12 months prior to enrollment either as part of routine care or clinical investigation;
    2. Meibomian gland expression within 6 months prior to enrollment;
    3. Blephex or debridement within 3 months prior to enrollment is an exclusion;
    4. Punctal occlusion or punctal plugs. Investigators can choose to remove the punctal plugs 15 days prior to enrollment;
    5. Use of TrueTear device within the past 2 weeks. (Subjects must refrain from using the TrueTear device for the duration of the study.); or
    6. Any history of meibomian gland probing
  • History of eyelid, conjunctiva or corneal surgery (including refractive surgery) within the past year. In addition, subjects with any history of the following are excluded: chalazion surgery, surgery on the tarsal conjunctiva, radial keratotomy (RK), complicated blepharoplasty, lid reconstruction, or significant complications post-refractive surgery.
  • Contact lens use within the past 2 weeks.
  • History of Ocular Herpes Simplex or Ocular Herpes Zoster
  • Any active, ocular or peri-ocular infection or inflammation
  • Recurrent clinically significant eye inflammation, other than dry eye, within 3 months prior to enrollment
  • Clinically significant anterior blepharitis. In addition, collarettes or flakes of more than one quarter of the eyelid are excluded.
  • Clinically significant eyelid abnormalities in either eye (e.g. entropion/ectropion, blepharospasm, aponeurotic ptosis, lagophthalmos, distichiasis, trichiasis).
  • Clinically significant dermatologic or cutaneous disease of the eyelid or periocular area.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
345 participants (actual)

Study arms

  • Experimental
    TearCare Group (Study Device) (Baseline to Month 24)

    TearCare System

    Device: TearCare System

  • Active comparator
    Restasis Group (Control) (Baseline to Month 6)

    Restasis® (0.05% Cyclosporine ophthalmic emulsion).

    Drug: Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion

  • Experimental
    Restasis group crossed over to TearCare (Month 6 to Month 12)

    Subjects originally randomized to Restasis stop Restasis use at Month 6 and receive a single TearCare treatment at Month 6 and are then followed through Month 12.

    Device: TearCare System

Interventions

  • DeviceTearCare System

    TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months.

  • DrugCyclosporine Ophthalmic EmulsionStudies of Cyclosporine Ophthalmic EmulsionCyclosporine Ophthalmic Emulsion pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At the Month 6 visit subjects will stop Restasis and receive a single TearCare treatment.

    Also known as: Restasis

06

What researchers measure

Primary outcomes

  1. Tear Break-Up Time

    Change in Tear Break-Up Time (TBUT) from baseline to month 6

    Time frame: 6 months

  2. OSDI Score

    Change in Ocular Surface Disease Index (OSDI) score from baseline to 6-months. The OSDI is a 12-item questionnaire that assesses symptoms of ocular irritation associated with dry eye and the impact of these on vision-related activities. The OSDI score ranges from 0 (best possible) to 100 (worst possible). The change in OSDI questionnaire from baseline to Month 6 is the difference between the scores at the two timepoints. A negative value would indicate improvement and a positive value, a worsening. The reported value is the mean of the change for all subjects.

    Time frame: 6 months

07

Results

Posted Nov 24, 2025

Participant flow

Primary Endpoint Phase
Participant flow — Primary Endpoint Phase
MilestoneTearCare Group (Study Device)Restasis Group (Control)
Started172173
Completed155163
Not completed1710
Withdrew: Withdrawal by subject77
Withdrew: Lost to follow-up32
Withdrew: Physician decision20
Withdrew: Other41
Withdrew: Protocol violation10
X-over-Restasis arm; Durability-TC arm
Participant flow — X-over-Restasis arm; Durability-TC arm
MilestoneTearCare Group (Study Device)Restasis Group (Control)
Started155163
Completed142161
Not completed132
Withdrew: Lost to follow-up70
Withdrew: Withdrawal by subject11
Withdrew: Physician decision10
Withdrew: Death10
Withdrew: Other31

Outcome measures

PrimaryTear Break-Up Time

Change in Tear Break-Up Time (TBUT) from baseline to month 6

Time frame:
6 months
Reported as:
Mean · seconds
Tear Break-Up Time
secondsTearCare Group (Study Device)Restasis Group (Control)
Tear Break-Up Time2.71 ± 3.351.22 ± 2.46
PrimaryOSDI Score

Change in Ocular Surface Disease Index (OSDI) score from baseline to 6-months. The OSDI is a 12-item questionnaire that assesses symptoms of ocular irritation associated with dry eye and the impact of these on vision-related activities. The OSDI score ranges from 0 (best possible) to 100 (worst possible). The change in OSDI questionnaire from baseline to Month 6 is the difference between the scores at the two timepoints. A negative value would indicate improvement and a positive value, a worsening. The reported value is the mean of the change for all subjects.

Time frame:
6 months
Reported as:
Mean · score on a scale
OSDI Score
score on a scaleTearCare Group (Study Device)Restasis Group (Control)
OSDI Score-18.25 ± 17.98-15.53 ± 19.86

Adverse events

Collected over 24 months; TearCare subjects were followed for 24 months while Restasis subjects were followed for 12 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TearCare Group (Study Device) (Baseline to 24 months)1/172 (0.6%)2/172 (1.2%)23/172 (13.4%)
Restasis Group (Control) (Baseline to Month 6)0/173 (0%)0/173 (0%)15/173 (8.7%)
Restasis Subjects crossed over to TearCare (Month 6- Month 120/163 (0%)0/163 (0%)8/163 (4.9%)
Most frequent serious events
Most frequent serious events
EventTearCare Group (Study Device) (Baseline to 24 months)Restasis Group (Control) (Baseline to Month 6)Restasis Subjects crossed over to TearCare (Month 6- Month 12
CholelithiasisGeneral disorders1/1720/1730/163
Pulmonary EdemaReproductive system and breast disorders1/1720/1730/163
Gall bladder tumorHepatobiliary disorders1/1720/1730/163
Most frequent other events
Showing 10 of 27
Most frequent other events
EventTearCare Group (Study Device) (Baseline to 24 months)Restasis Group (Control) (Baseline to Month 6)Restasis Subjects crossed over to TearCare (Month 6- Month 12
Loss of BCVA of ≥ 10 lettersEye disorders6/1722/1734/163
chalazionEye disorders4/1721/1730/163
New Onset Vitreous Floaters and PhotopsiaEye disorders0/1723/1731/163
Worsening of Dry EyeEye disorders2/1720/1730/163
Swelling of the eyelid(s)Eye disorders2/1720/1730/163
macular degenerationEye disorders2/1720/1730/163
Foreign body sensationEye disorders1/1722/1730/163
Discomfort post instillation of dropsEye disorders0/1722/1730/163
Eyelid irritationEye disorders1/1720/1731/163
Worsening of Preexisting conditionEye disorders0/1720/1731/163

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TearCare Group (Study Device)Restasis Group (Control)Total
<=18 years000
Between 18 and 65 years113114227
>=65 years5959118
Age, Continuous
Age, Continuous(years)TearCare Group (Study Device)Restasis Group (Control)Total
Mean55.5 ± 14.856.8 ± 13.156.2 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)TearCare Group (Study Device)Restasis Group (Control)Total
Female120128248
Male524597
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TearCare Group (Study Device)Restasis Group (Control)Total
Subject Demographics — Asian9716
Subject Demographics — Black/African American61218
Subject Demographics — White/Caucasian155151306
Subject Demographics — Other/mixed235
Region of Enrollment
Region of Enrollment(participants)TearCare Group (Study Device)Restasis Group (Control)Total
United States172173345
Tear Break Up Time
Tear Break Up Time(seconds)TearCare Group (Study Device)Restasis Group (Control)Total
Mean4.39 ± 1.264.37 ± 1.184.38 ± 1.21
OSDI
OSDI(units on a scale)TearCare Group (Study Device)Restasis Group (Control)Total
Mean50.0 ± 14.950.0 ± 14.950.0 ± 14.9
08

Study locations

14 sites
  • Doctor My Eyes
    Scottsdale, Arizona 85254, United States
  • Scripps Health
    La Jolla, California 92037, United States
  • Harvard Eye Associates
    Laguna Hills, California 92653, United States
  • Eye Research Foundation
    Newport Beach, California 92663, United States
  • Vision Institute
    Colorado Springs, Colorado 80907, United States
  • Loh Ophthalmology Associates
    Miami, Florida 33143, United States
  • Jackson Eye
    Lake Villa, Illinois 60046, United States
  • Cincinnati Eye Institute
    Edgewood, Kentucky 41017, United States
  • Kentucky Eye Institute
    Lexington, Kentucky 40517, United States
  • Vita Eye Clinic
    Shelby, North Carolina 28150, United States
  • Vantage Eye Care
    Bala-Cynwyd, Pennsylvania 19004, United States
  • University of Pittsburg-Ophthalmology Dept
    Pittsburgh, Pennsylvania 15213, United States
  • Vance Thompson Vision
    Sioux Falls, South Dakota 57108, United States
  • Parkhurst NuVision
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Hovanesian J, Ayres BD, Bloomenstein MR, Loh J, Chester T, Saenz B, Echegoyen J, Kannarr SR, Rodriguez TC, Dickerson JE Jr. Durability of the TearCare treatment effect in subjects with dry eye disease: Stage 3 of the Sahara randomized controlled trial. Optom Vis Sci. 2025 Aug 1;102(8):495-504. doi: 10.1097/OPX.0000000000002278. Epub 2025 Jul 25. PubMed 40719437 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Sep 2024, 40 months.

Results were first posted in Nov 2025, 1 year 2 months after primary completion.

Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 40 months is above that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2021
First posted
Mar 12, 2021
StartActual
Apr 28, 2021
Primary completionActual
Sep 23, 2024
CompletionActual
Sep 23, 2024
Results first posted
Nov 24, 2025
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04795752
Lead sponsor
Sight Sciences, Inc.
Responsible party
Sponsor
First posted
Mar 12, 2021
Start date
Apr 28, 2021
Primary completion
Sep 23, 2024
Completion
Sep 23, 2024
Results posted
Nov 24, 2025
Last update
Nov 24, 2025

Study contacts

Jaime Dickerson, PhD
study director · Sight Sciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion